Lion Group Holding Limited is an investment holding company focused on the research, development, manufacture and marketing of biopharmaceutical products in the People’s Republic of China. Established in the Cayman Islands and listed on the NASDAQ under the ticker symbol LGHL, the company has built a portfolio of proprietary and partnered therapies that address key medical needs in oncology, cardiovascular care, analgesia and anti‐inflammatory treatment.
The company’s main business activities encompass the full pharmaceutical value chain, from early‐stage discovery and clinical development through to commercial manufacturing and distribution. Lion Group’s in‐house research teams work on both small molecule and biologic drug candidates, while its manufacturing facilities operate under cGMP standards to support consistent quality and scale. The organization also collaborates with domestic and international partners to in-license promising drug assets and accelerate regulatory filings.
With a distribution network spanning over 30 provinces and municipalities in China, Lion Group serves hospitals, specialty clinics and retail pharmacies in Tier 1, 2 and 3 cities. The company has also begun exploring entry into selected Southeast Asian markets through local registration and alliances. Its sales and medical affairs teams engage healthcare professionals to support product launches, post-marketing surveillance and continuing medical education programs.
Lion Group is led by an executive management team with decades of experience in pharmaceutical research and operations. The board comprises industry veterans and independent directors who guide corporate governance and strategic planning. Over its history, the company has strengthened its pipeline through targeted acquisitions and joint ventures, positioning itself to address evolving patient needs and capitalize on growth opportunities in China’s rapidly expanding biopharma sector.
AI Generated. May Contain Errors.
